IR-Med (IRME) Net Income towards Common Stockholders (2020 - 2025)

IR-Med has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$286000.0 for Q2 2025.

• Net Income towards Common Stockholders for Q2 2025 came in at -$286000.0, up 20.11% year-over-year; the trailing twelve-month figure through Jun 2025 was -$1.5 million (up 57.87% YoY), and the FY2024 annual result was -$1.9 million, up 61.32% from the prior year.
• Net Income towards Common Stockholders came in at -$286000.0 for Q2 2025 at IR-Med, down from -$253000.0 in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$253000.0 in Q1 2025 to a low of -$2.1 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$864500.0 (2022), against an average of -$879277.8.
• Across the five-year window, Net Income towards Common Stockholders tumbled 802.5% in 2021 and soared 74.33% in 2024, its largest moves.
• IR-Med's Net Income towards Common Stockholders stood at -$1.0 million in 2021, then plunged by 105.17% to -$2.1 million in 2022, then jumped by 38.8% to -$1.3 million in 2023, then jumped by 74.33% to -$324000.0 in 2024, then gained by 11.73% to -$286000.0 in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$286000.0 (Q2 2025), -$253000.0 (Q1 2025), and -$324000.0 (Q4 2024), per Business Quant data.